These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Occupational Radiation Exposure of Radiopharmacy, Nuclear Medicine, and Surgical Personnel During Use of [ Aalbersberg EA; Verwoerd D; Mylvaganan-Young C; de Barros HA; van Leeuwen PJ; Sonneborn-Bols M; Donswijk ML J Nucl Med Technol; 2021 Dec; 49(4):334-338. PubMed ID: 34330802 [TBL] [Abstract][Full Text] [Related]
23. Yadav MP; Ballal S; Tripathi M; Damle NA; Sahoo RK; Seth A; Bal C Eur J Nucl Med Mol Imaging; 2017 Jan; 44(1):81-91. PubMed ID: 27506431 [TBL] [Abstract][Full Text] [Related]
25. Dosimetry Estimate and Initial Clinical Experience with Rathke H; Flechsig P; Mier W; Bronzel M; Mavriopoulou E; Hohenfellner M; Giesel FL; Haberkorn U; Kratochwil C J Nucl Med; 2019 Jun; 60(6):806-811. PubMed ID: 30389816 [TBL] [Abstract][Full Text] [Related]
26. Influence of short-term dexamethasone on the efficacy of Derlin T; Sommerlath Sohns JM; Schmuck S; Henkenberens C; von Klot CAJ; Ross TL; Bengel FM Prostate; 2020 May; 80(8):619-631. PubMed ID: 32187729 [TBL] [Abstract][Full Text] [Related]
27. Prospects of medium specific activity (177) Lu in targeted therapy of prostate cancer using (177) Lu-labeled PSMA inhibitor. Chakraborty S; Chakravarty R; Shetty P; Vimalnath KV; Sen IB; Dash A J Labelled Comp Radiopharm; 2016 Jul; 59(9):364-71. PubMed ID: 27264278 [TBL] [Abstract][Full Text] [Related]
28. Delayed response after repeated Rahbar K; Bögeman M; Yordanova A; Eveslage M; Schäfers M; Essler M; Ahmadzadehfar H Eur J Nucl Med Mol Imaging; 2018 Feb; 45(2):243-246. PubMed ID: 29134280 [TBL] [Abstract][Full Text] [Related]
29. German Multicenter Study Investigating 177Lu-PSMA-617 Radioligand Therapy in Advanced Prostate Cancer Patients. Rahbar K; Ahmadzadehfar H; Kratochwil C; Haberkorn U; Schäfers M; Essler M; Baum RP; Kulkarni HR; Schmidt M; Drzezga A; Bartenstein P; Pfestroff A; Luster M; Lützen U; Marx M; Prasad V; Brenner W; Heinzel A; Mottaghy FM; Ruf J; Meyer PT; Heuschkel M; Eveslage M; Bögemann M; Fendler WP; Krause BJ J Nucl Med; 2017 Jan; 58(1):85-90. PubMed ID: 27765862 [TBL] [Abstract][Full Text] [Related]
30. Results of a Prospective Phase 2 Pilot Trial of Emmett L; Crumbaker M; Ho B; Willowson K; Eu P; Ratnayake L; Epstein R; Blanksby A; Horvath L; Guminski A; Mahon K; Gedye C; Yin C; Stricker P; Joshua AM Clin Genitourin Cancer; 2019 Feb; 17(1):15-22. PubMed ID: 30425003 [TBL] [Abstract][Full Text] [Related]
31. More advantages in detecting bone and soft tissue metastases from prostate cancer using Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003 [TBL] [Abstract][Full Text] [Related]
32. Poor Outcomes for Patients with Metastatic Castration-resistant Prostate Cancer with Low Prostate-specific Membrane Antigen (PSMA) Expression Deemed Ineligible for Thang SP; Violet J; Sandhu S; Iravani A; Akhurst T; Kong G; Ravi Kumar A; Murphy DG; Williams SG; Hicks RJ; Hofman MS Eur Urol Oncol; 2019 Nov; 2(6):670-676. PubMed ID: 31412006 [TBL] [Abstract][Full Text] [Related]
33. Therapeutic response and side effects of repeated radioligand therapy with 177Lu-PSMA-DKFZ-617 of castrate-resistant metastatic prostate cancer. Ahmadzadehfar H; Eppard E; Kürpig S; Fimmers R; Yordanova A; Schlenkhoff CD; Gärtner F; Rogenhofer S; Essler M Oncotarget; 2016 Mar; 7(11):12477-88. PubMed ID: 26871285 [TBL] [Abstract][Full Text] [Related]
36. Bräuer A; Grubert LS; Roll W; Schrader AJ; Schäfers M; Bögemann M; Rahbar K Eur J Nucl Med Mol Imaging; 2017 Sep; 44(10):1663-1670. PubMed ID: 28624848 [TBL] [Abstract][Full Text] [Related]
37. Radioligand Therapy With 177Lu-PSMA-617 as A Novel Therapeutic Option in Patients With Metastatic Castration Resistant Prostate Cancer. Rahbar K; Bode A; Weckesser M; Avramovic N; Claesener M; Stegger L; Bögemann M Clin Nucl Med; 2016 Jul; 41(7):522-8. PubMed ID: 27088387 [TBL] [Abstract][Full Text] [Related]
38. Lacrimal Glands May Represent Organs at Risk for Radionuclide Therapy of Prostate Cancer with [(177)Lu]DKFZ-PSMA-617. Hohberg M; Eschner W; Schmidt M; Dietlein M; Kobe C; Fischer T; Drzezga A; Wild M Mol Imaging Biol; 2016 Jun; 18(3):437-45. PubMed ID: 26920354 [TBL] [Abstract][Full Text] [Related]
39. Radioligand therapy of metastatic prostate cancer using Ahmadzadehfar H; Zimbelmann S; Yordanova A; Fimmers R; Kürpig S; Eppard E; Gaertner FC; Wei X; Hauser S; Essler M Oncotarget; 2017 Aug; 8(33):55567-55574. PubMed ID: 28903443 [TBL] [Abstract][Full Text] [Related]
40. Third-line treatment and von Eyben FE; Roviello G; Kiljunen T; Uprimny C; Virgolini I; Kairemo K; Joensuu T Eur J Nucl Med Mol Imaging; 2018 Mar; 45(3):496-508. PubMed ID: 29247284 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]